Business
Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":" MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Notice of Allowance has been received from the US Patent and Trademark Office (USPTO) for claims involving a novel method to treat cancer stem cells (CSC’s). The allowed US patent protects proprietary claims capturing methods and uses for pancreatic proenzymes to treat cancer by specifically targeting and eradicating CSCs.\n\nCSCs represent only a small fraction of the cell population within a tumor and can remain dormant for periods of time, thereby evading standard treatment approaches like radiation and chemotherapy that target dividing cells. Therefore, a priority for improving treatment and reducing risk of relapse is to develop a strategy that targets CSC eradication, whilst leaving healthy cells alone. This continues to be a specific area of focus as the Company’s lead product candidate, PRP, advances to a First-In-Human study for the treatment of patients with late-stage solid tumors.\n\nThe allowed patent, citing the novel CSC treatment method, is currently one of 4 patent families, consisting of 65 patents either in force, or pending in global jurisdictions. It is the first allowed by the USPTO covering a method of minimizing the progression of cancer in a patient by administering a therapeutically effective amount of two proenzymes, trypsinogen and chymotrypsinogen, thereby preventing metastatic cancer in the patient by targeting and eradicating CSCs from solid tumors.\n\n“The allowance of this patent by the USPTO is a significant step for our intellectual property portfolio in the biggest global healthcare market in the world and confirms our claims cover a novel therapeutic approach for the treatment and prevention of metastatic cancer, which is the main cause of patient death for sufferers,” said James Nathanielsz, Propanc’s Chief Executive Officer. “It is especially important to continue to expand and grow our intellectual property portfolio, as we advance further along the drug development pathway. Additional patent applications are anticipated and we are excited about the growth and commercial potential of our portfolio with the goal of creating significant, l...